Uniplan Investment Counsel Inc. trimmed its holdings in Psychemedics Corp. (NASDAQ:PMD) by 10.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,171 shares of the company’s stock after selling 17,761 shares during the quarter. Uniplan Investment Counsel Inc. owned about 2.73% of Psychemedics worth $2,824,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Seizert Capital Partners LLC raised its position in shares of Psychemedics by 30.3% during the 3rd quarter. Seizert Capital Partners LLC now owns 30,179 shares of the company’s stock valued at $568,000 after buying an additional 7,015 shares during the period. Quantum Capital Management raised its position in shares of Psychemedics by 7.0% during the 2nd quarter. Quantum Capital Management now owns 50,521 shares of the company’s stock valued at $972,000 after buying an additional 3,316 shares during the period. North Star Investment Management Corp. raised its position in shares of Psychemedics by 6.1% during the 3rd quarter. North Star Investment Management Corp. now owns 81,277 shares of the company’s stock valued at $1,529,000 after buying an additional 4,654 shares during the period. Crawford Investment Counsel Inc. raised its position in shares of Psychemedics by 4.0% during the 3rd quarter. Crawford Investment Counsel Inc. now owns 255,284 shares of the company’s stock valued at $4,802,000 after buying an additional 9,743 shares during the period. Finally, Deprince Race & Zollo Inc. raised its position in shares of Psychemedics by 388.7% during the 3rd quarter. Deprince Race & Zollo Inc. now owns 288,147 shares of the company’s stock valued at $5,420,000 after buying an additional 229,180 shares during the period. 57.37% of the stock is currently owned by institutional investors and hedge funds.

In related news, VP Michael I. Schaffer sold 6,324 shares of Psychemedics stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $19.23, for a total value of $121,610.52. Following the completion of the sale, the vice president now owns 28,624 shares in the company, valued at approximately $550,439.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.90% of the stock is currently owned by company insiders.

PMD stock opened at $17.01 on Wednesday. The company has a market cap of $96.27 million, a PE ratio of 19.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.73 and a current ratio of 2.73. Psychemedics Corp. has a one year low of $16.11 and a one year high of $22.88.

Psychemedics (NASDAQ:PMD) last released its quarterly earnings results on Tuesday, October 23rd. The company reported $0.23 EPS for the quarter. The firm had revenue of $11.02 million for the quarter. Psychemedics had a net margin of 14.24% and a return on equity of 26.58%.

The company also recently declared a quarterly dividend, which was paid on Monday, November 12th. Stockholders of record on Friday, November 2nd were given a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 4.23%. The ex-dividend date was Thursday, November 1st.

Separately, ValuEngine raised shares of Psychemedics from a “hold” rating to a “buy” rating in a research report on Friday, October 12th.

WARNING: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/uniplan-investment-counsel-inc-decreases-holdings-in-psychemedics-corp-pmd/2662850.html.

Psychemedics Company Profile

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.

Recommended Story: Treasury Bonds

Institutional Ownership by Quarter for Psychemedics (NASDAQ:PMD)

Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.